Literature DB >> 24129894

Impact of the type of ultrasound probe on prostate cancer detection rate and characterization in patients undergoing MRI-targeted prostate biopsies using cognitive fusion.

Guillaume Ploussard1, Samuel Aronson, Vincent Pelsser, Mark Levental, Maurice Anidjar, Franck Bladou.   

Abstract

PURPOSE: To assess the impact of ultrasound probe (end fire vs. side fire) during MRI-targeted prostate biopsy using cognitive fusion.
METHODS: Inclusion criteria were as follows: consecutive patients undergoing prostate biopsies after multiparametric MRI; no PSA above 10 ng/ml; no clinical bulking disease; MRI areas suspicious for malignancy. From January 2011 to December 2012, 91 patients were included. A standard 10 TRUS-guided biopsy protocol plus 2 targeted biopsies at any MRI lesion was used. Patient's characteristics, MRI findings, and pathology evaluations were compared between the two groups.
RESULTS: Mean patient age and PSA were 63 years and 5.95 ng/ml, respectively. The median number of MRI lesions was 2, and the mean volume of the index lesion was 0.64 cc. The overall PCa detection rate was 58.2 %. The MRI scoring system was significantly predictive for PCa detection and aggressiveness (p < 0.001). There was a not statistically significant trend toward greater PCa detection rate (+23 %) in the end-fire cohort (p = 0.235). The PCa detection rate is significantly improved by 1.7-fold in case of MRI score 4-5 lesion as compared to MRI score 3 lesion (p = 0.031) when using the end-fire probe. Conversely, the MRI score does not significantly influence the detection rate in the side-fire group (p = 0.250). The improvement in the PCa detection rate by the end-fire probe was predominantly reported in anterior and of apical peripheral MRI lesions.
CONCLUSION: In case of high MRI score lesions, the PCa detection rate is significantly improved when using end-firing, particularly in case of anterior and apical peripheral lesions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24129894     DOI: 10.1007/s00345-013-1186-0

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  22 in total

1.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authors:  Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni
Journal:  Eur Urol       Date:  2010-10-28       Impact factor: 20.096

2.  Type of transrectal ultrasonography probe influences prostate cancer detection rates on repeat prostate biopsy.

Authors:  Christina B Ching; Osama Zaytoun; Ayman S Moussa; Jianbo Li; Anthony Avallone; J Stephen Jones
Journal:  BJU Int       Date:  2011-11-01       Impact factor: 5.588

3.  Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection.

Authors:  Jérémie Haffner; Laurent Lemaitre; Philippe Puech; Georges-Pascal Haber; Xavier Leroy; J Stephen Jones; Arnauld Villers
Journal:  BJU Int       Date:  2011-03-22       Impact factor: 5.588

4.  Does the transrectal ultrasound probe influence prostate cancer detection in patients undergoing an extended prostate biopsy scheme? Results of a large retrospective study.

Authors:  Marco Raber; Vincenzo Scattoni; Andrea Gallina; Massimo Freschi; Eduardo Pedroso De Almeyda; Valerio Di Girolamo; Francesco Montorsi; Patrizio Rigatti
Journal:  BJU Int       Date:  2011-08-22       Impact factor: 5.588

5.  Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population.

Authors:  Osama M Zaytoun; Ayman S Moussa; Tianming Gao; Khaled Fareed; J Stephen Jones
Journal:  J Urol       Date:  2011-07-23       Impact factor: 7.450

6.  Does transrectal ultrasound probe configuration really matter? End fire versus side fire probe prostate cancer detection rates.

Authors:  Christina B Ching; Ayman S Moussa; Jianbo Li; Brian R Lane; Craig Zippe; J Stephen Jones
Journal:  J Urol       Date:  2009-03-14       Impact factor: 7.450

7.  Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis.

Authors:  Patrick J Bastian; Leslie A Mangold; Jonathan I Epstein; Alan W Partin
Journal:  Cancer       Date:  2004-11-01       Impact factor: 6.860

Review 8.  Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance.

Authors:  Arnauld Villers; Laurent Lemaitre; Jérémie Haffner; Philippe Puech
Journal:  Curr Opin Urol       Date:  2009-05       Impact factor: 2.309

Review 9.  MRI-ultrasound fusion for guidance of targeted prostate biopsy.

Authors:  Leonard Marks; Shelena Young; Shyam Natarajan
Journal:  Curr Opin Urol       Date:  2013-01       Impact factor: 2.309

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  3 in total

1.  Endorectal multiparametric 3-tesla magnetic resonance imaging associated with systematic cognitive biopsies does not increase prostate cancer detection rate: a randomized prospective trial.

Authors:  Gianluigi Taverna; Giorgio Bozzini; Fabio Grizzi; Mauro Seveso; Alberto Mandressi; Luca Balzarini; Federica Mrakic; Pietro Bono; Oliviero De Franceco; NicolòMaria Buffi; Giovanni Lughezzani; Massimo Lazzeri; Paolo Casale; Giorgio Ferruccio Guazzoni
Journal:  World J Urol       Date:  2015-10-19       Impact factor: 4.226

2.  Transrectal ultrasound-guided biopsy for prostate cancer detection: Systematic and/or magnetic-resonance imaging-targeted.

Authors:  Franck Bladou; Cora Fogaing; Mark Levental; Samuel Aronson; Mona Alameldin; Maurice Anidjar
Journal:  Can Urol Assoc J       Date:  2017-09       Impact factor: 1.862

3.  Accuracy of cognitive MRI-targeted biopsy in hitting prostate cancer-positive regions of interest.

Authors:  Yannick Cerantola; Eléonore Haberer; Jose Torres; Mona Alameldin; Samuel Aronson; Mark Levental; Franck Bladou; Maurice Anidjar
Journal:  World J Urol       Date:  2015-05-17       Impact factor: 4.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.